AKBA Overview

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with two commercial products for patients impacted by kidney disease. The Company's portfolio includes Vafseo and Auryxia. Vafseo is an orally administered medicine, approved by the United States Food and Drug Administration (FDA), for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis for at least three months. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA) in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). The Company's development pipeline includes mid-stage rare kidney disease pipeline assets (praliciguat and AKB-097) and early-stage pipeline assets (AKB-9090 and AKB-10108), which are HIF molecules.

Wall Street analysts forecast AKBA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AKBA is5.00 USD with a low forecast of 4.00 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Akebia Therapeutics Inc revenue for the last quarter amounts to 57.62M USD, increased 23.93

Akebia Therapeutics Inc. EPS for the last quarter amounts to -0.05 USD, decreased -50.00

Akebia Therapeutics Inc (AKBA) has 194 emplpoyees as of April 17 2026.

Today AKBA has the market capitalization of 361.64M USD.